Skip to main content
. Author manuscript; available in PMC: 2016 Jun 13.
Published in final edited form as: Cardiovasc Hematol Agents Med Chem. 2009 Jul;7(3):234–250. doi: 10.2174/187152509789105444

Table 2.

Kallikrein inhibitors with structural diversity and varying potency reported in the literature

Organization Drug Name Structure Highest Phase MOA Condition Basic Patent
Fovea,Cubist: Dyax DX-88 graphic file with name nihms786745t1.jpg Recommended Approal Plasma Kallikrfein inhibitor Surgery, arterial coronary; Angioedema, hereditary; Edema, macular US 2006183771; WO 2006036860
Showa Denko PKSI-527 graphic file with name nihms786745t2.jpg Preclinical Plasma Kallikrein inhibitor Thrombosis EP 0217286
Daiichi Sankyo graphic file with name nihms786745t3.jpg Biological Testing Plasma Kallikrein inhibitor Pancreatitis JP 1992159261
Novo Nordisk graphic file with name nihms786745t4.jpg Biological Testing Plasma Kallikrein inhibitor Pancreatitis US 5373090
Bristol-Meyers Squibb graphic file with name nihms786745t5.jpg Biological Testing Kallikrein 1 (Plasma Kallikrein) Inhibitors; Inhibitors of Blood Coagulation Pathways Thrombosis WO 1997038984
Celera graphic file with name nihms786745t6.jpg Biological Testing Plasmin Inhibitors; Urokinase (u-PA) Inhibitors; Kallikrein 1 (Plasma Kallikrein) Inhibitors Thrombosis WO 2000035886

Source: Prous Integrity